Vertex falls after Q4 profit, sales of gene therapy disappoint

Vertex Pharmaceuticals

11/02/2025 17:32

** Shares of drugmaker Vertex Pharmaceuticals  VRTX.O  fall
1.8% to $461 in morning trade 
    ** Co on Monday reported Q4 profit of $3.98/shr, missing
analysts' est. of $4.03/shr - as per LSEG data 
    ** Q4 sales of co and partner CRISPR's  CRSP.BN  sickle-cell
disease therapy, Casgevy, came in at $8 mln vs est. of $17.7 mln
    ** Brokerage TD Cowen says sales of Casgevy could be hurt by
adoption and manufacturing-related challenges; does not expect
VRTX to post billion-dollar revenues for the therapy
    ** VRTX forecast 2025 rev. of $11.75 bln to $12.0 bln, vs.
est. of $11.84 bln
    ** Co said it aims to launch five new treatments by 2028,
which includes a next-generation cystic fibrosis drug and its
recently approved non-opioid painkiller, Journavx
    ** Stock has risen 11% in the last 12 months

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))